Tower Research Capital LLC TRC Has $442,000 Position in 10x Genomics, Inc. (NASDAQ:TXG)

Tower Research Capital LLC TRC boosted its holdings in 10x Genomics, Inc. (NASDAQ:TXG) by 632.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 30,764 shares of the company’s stock after acquiring an additional 26,565 shares during the period. Tower Research Capital LLC TRC’s holdings in 10x Genomics were worth $442,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the business. Signaturefd LLC grew its position in shares of 10x Genomics by 424.6% in the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock valued at $26,000 after purchasing an additional 1,452 shares during the last quarter. Blue Trust Inc. grew its holdings in 10x Genomics by 73.1% in the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company’s stock valued at $44,000 after buying an additional 1,299 shares in the last quarter. Sound Income Strategies LLC increased its position in 10x Genomics by 65.2% during the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock worth $48,000 after buying an additional 1,330 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of 10x Genomics during the fourth quarter worth $52,000. Finally, SRS Capital Advisors Inc. boosted its position in shares of 10x Genomics by 817.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company’s stock valued at $70,000 after acquiring an additional 4,324 shares during the period. Institutional investors and hedge funds own 84.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Stifel Nicolaus lowered their price target on shares of 10x Genomics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Citigroup lowered their target price on shares of 10x Genomics from $20.00 to $15.00 and set a “buy” rating on the stock in a report on Tuesday, March 4th. UBS Group cut their price target on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a research note on Thursday, February 13th. Barclays reduced their price target on 10x Genomics from $15.00 to $12.00 and set an “overweight” rating on the stock in a research report on Thursday, April 10th. Finally, Leerink Partners cut 10x Genomics from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $25.00 to $12.00 in a report on Thursday, February 13th. One analyst has rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $19.79.

10x Genomics Trading Down 1.2 %

TXG stock opened at $8.38 on Wednesday. 10x Genomics, Inc. has a 12 month low of $6.78 and a 12 month high of $29.37. The stock has a market capitalization of $1.02 billion, a P/E ratio of -5.51 and a beta of 2.01. The firm has a 50-day moving average price of $9.34 and a 200-day moving average price of $12.95.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. As a group, equities analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Insider Activity

In related news, Director Alan Mateo purchased 40,000 shares of the firm’s stock in a transaction dated Friday, February 21st. The stock was bought at an average price of $11.14 per share, with a total value of $445,600.00. Following the completion of the purchase, the director now owns 61,691 shares in the company, valued at approximately $687,237.74. This represents a 184.41 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Benjamin J. Hindson sold 4,573 shares of the firm’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $50,623.11. Following the transaction, the insider now owns 335,324 shares of the company’s stock, valued at $3,712,036.68. This trade represents a 1.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 10.03% of the stock is currently owned by insiders.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.